AUROPHARMAAurobindo Pharma Ltd.
Aurobindo Pharma Q2 FY27 Results: Consolidated Net Profit ₹1,124 Crore on Total Income of ₹10,432 Crore
- Earnings
- pharmaceuticals
Reviewed byRachit TripathiBlacklitt Research
Aurobindo Pharma (NSE: AUROPHARMA) reported consolidated total income of ₹10,431.51 crore and net profit of ₹1,123.84 crore for the quarter ended 30 Sep 2026, it said in a filing on 04 Nov 2026. Standalone total income was ₹3,280.13 crore and standalone net profit ₹723.58 crore for the same quarter.
Key highlights
Consolidated
Including its subsidiaries
- Total income: ₹10,431.51 crore, up 24.1% YoY and 10.8% QoQ
- Net profit and EPS: ₹1,123.84 crore, up 32.5% YoY; basic EPS ₹19.57
- Finance costs: ₹102.21 crore, up 7.3% YoY and 0.5% QoQ
- Exceptional item: ₹40.18 crore in the half year, Lannett acquisition costs
Standalone
The company on its own, without its subsidiaries
- Total income: ₹3,280.13 crore, up 13.5% YoY and 7.8% QoQ
- Net profit and EPS: ₹723.58 crore, up 24.5% YoY; basic EPS ₹12.58
- Other income: ₹102.80 crore, down 35.6% YoY
Summary
| Particulars | Q2 FY27 | Q2 FY26 | YoY | Q1 FY27 | QoQ |
|---|---|---|---|---|---|
| 10,431.51 | 8,406.29 | +24.1% | 9,414.58 | +10.8% | |
| Revenue from operations | 10,263.29 | 8,285.70 | +23.9% | 9,150.35 | +12.2% |
| Other income | 168.22 | 120.59 | +39.5% | 264.23 | -36.3% |
| 1,123.84 | 848.13 | +32.5% | 1,032.03 | +8.9% | |
| Profit before tax | 1,687.67 | 1,275.92 | +32.3% | 1,515.09 | +11.4% |
| Finance costs | 102.21 | 95.24 | +7.3% | 101.66 | +0.5% |
| Depreciation | 531.15 | 429.19 | +23.8% | 486.82 | +9.1% |
| Tax expense | 563.83 | 427.79 | +31.8% | 483.06 | +16.7% |
| Net profit margin | 10.77% | 10.09% | +0.68 pp | 10.96% | -0.19 pp |
| EPS, basic (₹) | 19.57 | 14.61 | +33.9% | 17.86 | +9.6% |
Figures are in ₹ crore; YoY compares with Q2 FY26 and QoQ with Q1 FY27. Click Total income or Net profit to see the rows behind them.
Consolidated net profit grew faster than total income over the year: net profit rose 32.5% to ₹1,123.84 crore while total income rose 24.1%. Profit before tax rose 32.3%, close to the profit growth, and tax expense rose 31.8% to ₹563.83 crore, so the tax charge moved broadly in step with profit.
Other income is a small part of the group's earnings this quarter. At ₹168.22 crore it is 1.6% of total income and 10.0% of profit before tax, against ₹120.59 crore a year earlier. Finance costs of ₹102.21 crore are 1.0% of total income, and rose 7.3% against a 24.1% rise in total income.
The quarter follows the Lannett Company LLC acquisition, completed on 29 Jun 2026 for a purchase consideration of about ₹2,321.83 crore (USD 245.7 million). The filing does not give Lannett's contribution to revenue or profit for the quarter.
Quarter-on-quarter, net profit rose 8.9% while total income rose 10.8%. Profit before tax rose 11.4%, and tax expense rose 16.7%, so the tax charge grew faster than profit before tax in the quarter. The filing gives no reason for that change.
| Particulars | Q2 FY27 | Q2 FY26 | YoY | Q1 FY27 | QoQ |
|---|---|---|---|---|---|
| 3,280.13 | 2,889.45 | +13.5% | 3,041.40 | +7.8% | |
| Revenue from operations | 3,177.33 | 2,729.93 | +16.4% | 2,799.51 | +13.5% |
| Other income | 102.80 | 159.52 | -35.6% | 241.89 | -57.5% |
| 723.58 | 581.37 | +24.5% | 737.22 | -1.9% | |
| Profit before tax | 970.95 | 756.41 | +28.4% | 1,008.08 | -3.7% |
| Finance costs | 48.09 | 57.44 | -16.3% | 47.07 | +2.2% |
| Depreciation | 69.52 | 67.00 | +3.8% | 68.99 | +0.8% |
| Tax expense | 247.37 | 174.17 | +42.0% | 270.86 | -8.7% |
| Net profit margin | 22.06% | 20.12% | +1.94 pp | 24.24% | -2.18 pp |
| EPS, basic (₹) | 12.58 | 10.01 | +25.7% | 12.75 | -1.3% |
Figures are in ₹ crore; YoY compares with Q2 FY26 and QoQ with Q1 FY27. Click Total income or Net profit to see the rows behind them.
Standalone net profit rose 24.5% to ₹723.58 crore, below the 28.4% rise in profit before tax to ₹970.95 crore. The figures show the tax charge growing faster than pre-tax profit.
Revenue from operations rose 16.4% to ₹3,177.33 crore, while other income fell 35.6% to ₹102.80 crore. Other income is 3.1% of total income this quarter, against 5.5% a year earlier. Finance costs fell 16.3% to ₹48.09 crore.
The standalone figures include a loss from discontinued operations of ₹0.87 crore in the quarter, linked to the transfer of the domestic branded generic formulations business to Auropharm Limited with effect from 1 Apr 2026. Standalone net profit fell 1.9% quarter-on-quarter while total income rose 7.8%.
Inference
The filing declares an interim dividend of ₹7.00 per equity share of ₹1 face value, with a record date of 11 Nov 2026 and payment on or before 20 Nov 2026. The filing does not state the total payout.
The filing also reports a proposal to merge Auroactive Pharma Private Limited with Apitoria Pharma Private Limited, approved by their boards and subject to NCLT approval, and a transfer of Auro Pharma LLC, Russia, between subsidiaries.
Not stated: the reasons for the quarter's changes in tax, finance costs and other income, and the outcome of the postal ballot on the re-appointment of Mangalam Ramasubramanian Kumar as an independent director from 1 Apr 2027.
Filed with BSE on . Reference: Original filing (PDF)
Disclaimer:
The information available on this article is provided for education and informational purposes only. It does not constitute or provide financial, investment or trading advice and should not be construed as an endorsement of any specific stock or financial strategy in any form or manner. We do not make any representations or warranties regarding the quality, reliability, or accuracy of the information provided. This website may contain links to third-party content. We are not responsible for the content or accuracy of these external sources and do not endorse or verify the information provided by third parties. We are not liable for any decisions made or actions taken based on the information provided on this website.
